Recursion Pharmaceuticals, Inc. Class A (RXRX)

Recursion Pharmaceuticals' stock has experienced significant fluctuations in the past six months. Key events include Q3 2025 earnings, TUPELO trial results, insider selling, and negative financial performance. The company reported Q3 2025 earnings per share (EPS) of -$0.36, exceeding analysts' expectations of -$0.38. The stock jumped by 10.53% following promising Phase 1b/2 results from its TUPELO trial for familial adenomatous polyposis. There have been multiple instances of insider selling by company executives and directors between December 2025 and February 2026. The company has faced challenges including substantial operating losses and a high burn rate.

Information regarding specific demand seasonality for Recursion Pharmaceuticals' products and services is not explicitly available. The demand for its drug discovery platform and pipeline products would likely be driven by ongoing research needs in the pharmaceutical industry, the progression of clinical trials, and the prevalence of the diseases it aims to treat, rather than calendar-based seasonality.

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on decoding biology and chemistry through technological innovations. Its AI-driven operating system, Recursion OS, combines automation, data collection, and machine learning to accelerate drug development. The company has a pipeline of potential therapeutic assets, including REC-994, REC-2282, REC-4881, REC-3964, RBM39, REC-7735, and REC-4539, targeting oncology and rare diseases. Recursion collaborates with pharmaceutical firms and research institutions to extend its reach and validate its platform.

Recursion Pharmaceuticals is headquartered in Salt Lake City, Utah, and operates in the United States. While its primary operations are based in the U.S., some of its drug development information references EU5 for prevalence data, suggesting a potential future market focus or research considerations in these European regions.

Recursion Pharmaceuticals' brand reputation has been shaped by its innovative approach to drug discovery using AI and machine learning, and its clinical trial progress. Positive aspects include AI-driven innovation, strategic partnerships, and promising trial results. However, the company also faces reputational challenges due to its financial performance as a clinical-stage biotechnology company. Analysts have a consensus "Buy" rating for RXRX, with some recommending a "Strong Buy."

Recursion Pharmaceuticals has significant institutional ownership, with 459 institutional owners holding a total of 380,968,526 shares, representing 68% of the company's shares. Major institutional owners include Vanguard Group Inc., ARK Investment Management LLC, and BlackRock, Inc. Individual ownership includes CEO Christopher Gibson, who holds 1.6% of the company's shares as of July 2025. There have also been notable insider sales by Christopher Gibson, Blake Borgeson, Ben Taylor, and Najat Khan between December 2025 and February 2026.